(Reuters) - CHICAGO, Aug 3 - Boston Scientific Corp.'s
decision not to divest part of its Endosurgery business signaled
the medical devices company has confidence it can pare down its
sizable debt through other means and would be better off hanging
on to its most stable product line, analysts said.
The decision announced on Thursday to change course and keep
the business, which makes products used to treat gallstones,
kidney stones and to perform colonoscopies, is the first major
financial decision by Boston Scientific under its new chief
financial officer.
Read more at Reuters.com Bonds News
decision not to divest part of its Endosurgery business signaled
the medical devices company has confidence it can pare down its
sizable debt through other means and would be better off hanging
on to its most stable product line, analysts said.
The decision announced on Thursday to change course and keep
the business, which makes products used to treat gallstones,
kidney stones and to perform colonoscopies, is the first major
financial decision by Boston Scientific under its new chief
financial officer.
Read more at Reuters.com Bonds News
